Profit before tax stood at Rs 2,006.97 crore during the quarter, up 90.25% from Rs 1,054.86 crore recorded in Q2 FY25.
EBITDA stood at Rs 2,431.3 crore in Q2 FY26, registering 75.8% growth compared with Rs 1,382.7 crore in Q2 FY25. The EBITDA margin improved 1,040 basis points to 35.6% in Q2 FY26 from 25.2% in Q2 FY25.
U.S. sales for Q2 FY26 were Rs 2,762.4 crore, up 47.3% compared to Rs 1,875.3 crore in Q2 FY25, accounting for 40% of Lupin's global sales. The company received six ANDA approvals from the U.S. FDA and launched six products in the U.S. market during the quarter. Lupin now has 147 generic products in the U.S. market.
Lupin continues to be the third-largest pharmaceutical player in both the U.S. generic market and the overall U.S. prescription market (IQVIA Qtr. TRx Sep 2025). The company leads in 49 of its marketed generics in the U.S. and ranks among the top three in 113 products (IQVIA Qtr. Sep 2025 by extended units).
India sales for Q2 FY26 stood at Rs 2,077.7 crore, up 3.4% compared to Rs 2,009.6 crore in Q2 FY25, accounting for 30% of global sales. India Region Formulation sales rose 8.8% YoY, with six brand launches across therapies during the quarter. Lupin ranks as the eighth-largest company in the Indian pharmaceutical market (IQVIA MAT Sep 2025).
Other developed markets sales for Q2 FY26 were Rs 811.7 crore, up 18.9% YoY, accounting for 12% of Lupin's global sales.
Emerging markets sales stood at Rs 922.8 crore, up 45.3% YoY, accounting for 14% of global sales.
Global API sales were Rs 256.8 crore, down 12.8% YoY compared to Rs 294.4 crore in Q2 FY25, representing 4% of global sales.
Investment in R&D stood at Rs 509.1 crore (7.5% of sales) for the quarter, compared to Rs 448.1 crore (8.2% of sales) in Q2 FY25. Lupin received approvals for six ANDAs from the U.S. FDA during the quarter. Cumulative ANDA filings with the U.S. FDA stood at 433 as of 30 September 2025, with the company having received 341 approvals to date. The company now has 50 First-to-File (FTF) filings, including 20 exclusive FTF opportunities. Cumulative U.S. DMF filings stood at 91 as of 30 September 2025.
Nilesh Gupta, managing director, Lupin, said 'We are delighted to present one of our strongest performances ever in this second quarter of FY26. We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the U.S., emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments. We intend to leverage the performance of H1 to deliver a strong FY26'
Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The counter rose 0.77% to Rs 1,971.15 on the BSE.
Powered by Capital Market - Live News
Beware of fraudulent tips, unauthenticated news and advice on stock market.
At BOB Capital, your account security is our topmost priority. Beware of receiving fraudulent communications, unauthenticated trading tips and unsolicited calls on trading in stocks from unverified sources, received through Whatsapp, Telegram, SMS, Calls, etc and take an informed decision before investing.
What should you do if you receive a trading tip over phone or SMS?
Report unsolicited messages to the Stock Exchange on +91 8291833676 or on designated email id i.e. feedbk_invg@nse.co.in. Please visit here to understand better.
Please visit CVC website at pledge.cvc.nic.in and take "Integrity Pledge" to be an active part of the "Satark Bharat, Samriddh Bharat" (Vigilant India, Prosperous India).
Filing complaints on SCORES - Easy & quick: a. Register on SCORES portal scores.sebi.gov.in/ b. Mandatory details for filing complaints on SCORES are i. Name, PAN, Address, Mobile Number, E-mail ID. c. Benefits: i. Effective communication ii. Speedy redressal of the grievances.
Valued Customer,
BOB Capital Markets Limited (BOBCaps) is firmly committed to the safety of your wealth. We would like to bring to your notice certain precautions that you certainly must take against potential tele-fraudsters/ unscrupulous and unregistered portfolio managers:
ALWAYS AVOID
We would like to caution you against such fraudulent calls and SMSes and urge you to be alert. Follow the golden rule:
Do not share your Login Credentials or Passwords with anybody
BOBCaps employees / representatives never ask for your password.
Certain tele-fraudsters / unscrupulous and unregistered portfolio managers call customers or SMS them on the pretext of providing investment tips and lure them to invest through their bogus firms by promising huge profits.
Such deceitful callers ask the customer to share his/her login credentials with passwords to allow trading in their accounts, assuring huge returns.
Often trades done in the customer’s accounts are far from the best interest of the customers. Holdings of customers are often sold and with the funds, trades are then placed in illiquid securities at unrealistic prices.
At times, the holdings of customers are sold at prices detrimental to the customer. The so-called “portfolio manager” assures profits, which naturally does not materialize. Customers are deceived into providing access to their trading accounts, thereby allowing such fraudsters access to funds and securities available to execute trades, injurious to the customer’s interest.
In our continuous effort to keep you safeguard from the market related frauds and increase awareness while conducting trades, we request you to go through the Press Release issued by the NSE and would request you to ensure that you do not engage with the individuals and entities mentioned below: